Raymond James Financial
PMCB icon

Raymond James Financial’s PharmaCyte Biotech PMCB Stock Holding History

Raymond James Financial’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-44
Closed -$48 – 6276
2025
Q2 		$48 Buy
+44
New +$49 ﹤0.01% 6888

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Raymond James Financial's PMCB Position: Q3 2025 in Review

Raymond James Financial sold out of PharmaCyte Biotech (PMCB) in Q3 2025, closing a stake of 44 shares — an estimated $48 sold.

Raymond James Financial first reported a position in PMCB in Q2 2025 and held it in 1 quarter. The position peaked at $48 in Q2 2025. 23 funds tracked by Wall St. Rank hold PMCB as of Q3 2025.

  • Raymond James Financial reported no remaining PharmaCyte Biotech position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 44 PharmaCyte Biotech shares in Q3 2025, an estimated $48.
  • Raymond James Financial first reported a position in PharmaCyte Biotech in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's PharmaCyte Biotech position peaked at $48 in Q2 2025.
  • 23 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.